• Frontline Maintenance Niraparib Improves PFS in Ovarian Cancer

    • July 16, 2019
    • Posted By : admin
    • 0 Comment
    •   31 views

    Niraparib (Zejula) as a maintenance treatment demonstrated a statistically significant improvement in progression-free survival (PFS) compared with placebo in patients with ovarian cancer following first-line platinum-based chemotherapy, regardless of biomarker status, meeting the primary endpoint of the phase III PRIMA (ENGOT-OV26/GOG-3012) trial.1

    Under the Prescription Drug User Fee Act, the FDA must make a decision on the application by October 24, 2019.

  31 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!